TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01441440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine ER 75 mg/day (fixed dose)
Description: Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)
Description: Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
Study: NCT03707392

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control - Standard ostomy education
Description: Standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
Study: NCT03862534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF
Description: After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF + CTG
Description: After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
Study: NCT01644149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratis Jet Injector
Description: Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle and Syringe
Description: Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2011-2012 Fluzone trivalent inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2011-2012 Fluzone trivalent inactivated influenza vaccine
Study: NCT02241109

Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: progression monitoring by echocardiography
Study: NCT00704496

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pseudoephedrine
Description: Pseudoephedrine is a 240 mg PO per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine
Description: Pseudoephedrine is a 240 mg PO per day
Study: NCT01954914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
Study: NCT02001155

Intervention type: PROCEDURE
Intervention: Water Drinking Test
Description: The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.

Intervention type: PROCEDURE
Intervention: Water Drinking Test
Description: The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
Study: NCT00648245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006 Inhalation Solution
Description: 75 mg of BIO-11006 administered once per day for 21 days by nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006 Inhalation Solution
Description: 150 mg of BIO-11006 administered once per day for 21 days by nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006 Inhalation Solution
Description: 75 mg of BIO-11006 administered twice per day for 21 days by nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given once daily for 21 days by nebulizer
Study: NCT04332653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-I7
Description: Administered by intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Administered by intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Administered by intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Administered by intravenous (IV) injection
Study: NCT00648245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO-11006
Description: 125 mg BIO-11006 given twice per day for 21 days by nebulizer
Study: NCT04755621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training
Description: Core stability exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rocabado Exercises
Description: Exercises for Temporomandibular Disorders
Study: NCT01784757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201 capsule formulation
Description: Capsule formulation of ODM-201
Study: NCT01923831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
Study: NCT01954160

Intervention type: DEVICE
Group type: OTHER
Intervention: Symplicity Renal Denervation
Description: Renal denervation

Intervention type: DEVICE
Group type: OTHER
Intervention: Symplicity Renal Denervation
Description: Renal denervation
Study: NCT04304742

Intervention type: PROCEDURE
Intervention: hip standard radiography/ CT scan/ MRI
Description: hip standard radiography/ CT scan/ MRI
Study: NCT03584061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
Study: NCT03928158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ 696
Description: 50-100-200 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 40-80-160 mg tablet
Study: NCT01039870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: postoperative pain is controlled with local analgesics delivered via PVB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural analgesia
Description: postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
Study: NCT01941693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated care
Description: Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
Study: NCT00699764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine- adjuvanted GSK208141
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Intramuscular injection, 3 doses
Study: NCT03969732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1. amyloid PET；2. T807 PET
Description: 1. Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~2. Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)
Study: NCT02211625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label TRV734 125 mg
Description: 125 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRV734 blinded
Description: blinded, multiple ascending dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone IR 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TRV734-matched and oxycodone placebo
Study: NCT04435587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Pill
Description: 3 days of once daily oral ivermectin 600mcg/kg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined ART/hydroxychloroquine
Description: 1. Day 1 hydroxychloroquine 400mg bid, Day2-5 hydroxychloroquine 200mg bid~2. Darunavir/ritonavir (400/100mg) q 12 hours for 5 days
Study: NCT01028885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy treatment planning/simulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Study: NCT01441440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
Study: NCT01248234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
Study: NCT01028885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Study: NCT03151343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Sugar pill, visually identical to active comparator
Study: NCT03945214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minute per day, 8 week digital meditation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating
Description: A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation + healthy eating
Description: 10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
Study: NCT02847975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium nitrate
Description: Sodium nitrate will be ingested orally
Study: NCT03108274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.
Study: NCT01248234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
Study: NCT04332653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Administered by intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Administered by intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Administered by intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Administered by intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Administered by intravenous (IV) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: Administered by intravenous (IV) injection
Study: NCT03219502

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03774381

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve B-3
Description: 160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: 160 mg of placebo is orally administered per day for 12 weeks.
Study: NCT03219502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Undergo rTMS

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham rTMS
Study: NCT03108274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral syrup.
Study: NCT01248234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol and Etomidate
Description: Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
Study: NCT03389126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
Study: NCT04329611

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine
Description: COVID19

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: COVID19
Study: NCT02929095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: - remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: - remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
Study: NCT02126904

Intervention type: DRUG
Intervention: IVA group
Study: NCT04492956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT02844101

Intervention type: DEVICE
Group type: OTHER
Intervention: GT3X Actigraph accelerometer.

Intervention type: DEVICE
Group type: OTHER
Intervention: GT3X Actigraph accelerometer.
Study: NCT01798784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweepstake Incentive 1
Description: Daily sweepstake conditional on daily medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweepstake Incentive 2
Description: Daily sweepstake conditional on daily medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweepstake Incentive 3
Description: Daily sweepstake conditional on daily medication adherence
Study: NCT00630578

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Cognitive Processing Therapy
Description: Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
Study: NCT01957150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol
Description: Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
Study: NCT01139294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylenex
Description: 1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
Study: NCT01879631

Intervention type: PROCEDURE
Intervention: radial keratotomy
Study: NCT04329299

Intervention type: DIAGNOSTIC_TEST
Intervention: blood-based biomarkers analyses
Description: Analyses of H. pylori antibodies/pepsinogen levels, micro RNAs (miRNAs) or blood-based protein markers levels in participants' blood samples
Study: NCT03710044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks.
Study: NCT03245892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel
Description: Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel
Description: Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV over approximately 30 min on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg every 6 weeks x 3-6 cycles in the neoadjuvant setting (maximum 2 doses of ipilimumab)
Study: NCT01986374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG is introduced
Description: must have good blastocysts
Study: NCT05684003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise based injury-prevention program
Description: Neuromuscular exercise based injury-prevention program
Study: NCT01529593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled